{"id":"lasw1835","safety":{"commonSideEffects":[{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Tremor"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"PDE4 inhibition leads to accumulation of cyclic adenosine monophosphate (cAMP) in immune and inflammatory cells, suppressing the release of pro-inflammatory cytokines and chemokines. This mechanism is intended to reduce airway inflammation and improve lung function in inflammatory airway diseases. The drug is being developed for respiratory indications where PDE4-mediated inflammation plays a pathogenic role.","oneSentence":"LASW1835 is a selective inhibitor of phosphodiesterase 4 (PDE4) that reduces inflammatory mediator production by increasing intracellular cAMP levels.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:18:18.661Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chronic obstructive pulmonary disease (COPD)"},{"name":"Asthma"}]},"trialDetails":[{"nctId":"NCT01726933","phase":"PHASE3","title":"LAS41008 in Moderate to Severe Chronic Plaque Psoriasis","status":"COMPLETED","sponsor":"Almirall, S.A.","startDate":"2012-11","conditions":"Plaque Psoriasis","enrollment":839}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Fumaderm initial/ Fumaderm"],"phase":"phase_3","status":"active","brandName":"LASW1835","genericName":"LASW1835","companyName":"Almirall, S.A.","companyId":"almirall-s-a","modality":"Small molecule","firstApprovalDate":"","aiSummary":"LASW1835 is a selective inhibitor of phosphodiesterase 4 (PDE4) that reduces inflammatory mediator production by increasing intracellular cAMP levels. Used for Chronic obstructive pulmonary disease (COPD), Asthma.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}